Compare Merck & Co., Inc. (MRK) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs VanEck Rare Earth/Strategic Metals — how do they compare? Merck & Co., Inc. trades at $133.35 (market cap $327.94B), while VanEck Rare Earth/Strategic Metals trades at $76.47. The key difference: Merck & Co., Inc. pays a 2.56% dividend while VanEck Rare Earth/Strategic Metals pays none, and Merck & Co., Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| MRK | REMX | |
|---|---|---|
Market Cap | $327.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $132.93 | $109.53 |
52-Week Low | $77.60 | $56.60 |
Enterprise Value | $374.70B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $65.01B in 2025 with net income of $18.25B, though 2026 projections show lower profitability. Recent acquisition activity includes the $6.7B tender offer for Terns Pharmaceuticals to bolster oncology pipeline.
Merck maintains solid fundamentals with 67.6% analyst buy ratings and $140.58 consensus target, offering 7.8% upside. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The stock presents a balanced opportunity with strong institutional support but faces margin compression headwinds in 2026.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.03, down 1.81% with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to 38 global rare earth companies, though key financial ratios remain undisclosed. Recent news highlights U.S. efforts to secure critical minerals supply chains amid China's export controls, with Energy Fuels expanding domestic production capacity.
Outlook hinges on geopolitical rare earth dynamics and U.S. supply chain independence initiatives. Risks include high volatility (~50% annualized) and China concentration. Analyst sentiment is mixed due to thematic reliance on policy shifts and commodity cycles, warranting caution for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
